Not provided
Not provided
Not provided
Not provided
Not provided
slow enrollment due to cost of medication and conflict of interest enrolling uninsured patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
By doing this study, researchers hope to learn if applying Santyl to the burn during the healing process affects the appearance of the resulting scar.
Subjects who have minor, second degree burns may be enrolled in this study. Subjects will receive either Santyl ointment or bacitracin ointment to apply to the burn until it heals. Bandages will be used to keep the burn covered while it heals. Second degree burns generally leave a scar. Once the burn heals, lotion and an appropriate bandage will be used to try to minimize the appearance of a scar.
The study hypothesis is that burns treated with Santyl will have a better scar appearance than burns treated with bacitracin.
Subjects enrolled in this study will make once a week visits to the University of Kansas Medical Center outpatient burn clinic until the burn heals. The burn will be assessed for healing at these visits. Once healed, visits to the clinic will be at 60 & 180 days, up to 6 months. At these visits, the appearance of the scar will be evaluated.
This study was originally funded by Smith and Nephew, but Smith and Nephew is no longer providing support for the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Collagenase Santyl | Active Comparator | Applied topically (2 mm thickness once daily) |
|
| Bacitracin | Sham Comparator | Applied topically (2 mm thickness) once daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Collagenase Santyl | Drug | A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects With at Least 95% Wound Healing | Outcome will be reported as number of subjects with at least 95% wound healing | 21 Days After Treatment |
| Number of Subjects With at Least 95% Wound Healing | Outcome will be reported as number of subjects with at least 95% wound epithelialization | 14 days after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Vancouver Scar Scale | Scar appearance will be documented using the Vancouver Scar Scale. It assesses 4 variables: vascularity, height/thickness, pliability, and pigmentation. VSS is derived by adding the score for each variable. Details of VSS is below. The Vancouver Scar Scale Pigmentation (0-2) Normal 0 Hypopigmentation 1 Hyperpigmentation 2 Range of Score: 0-2 with 0 = best outcome, 2 = worst outcome Vascularity (0-3) Normal. 0 Pink 1 Red 2 Purple. 3 Range: 0-3 with 0 = best outcome, 3 = worst outcome Pliability (0-5) Normal 0 Supple 1 Yielding 2 Firm 3 Banding 4 Contracture 5 Range of Score: 0-5, with 0 = best outcome, 5 = worst outcome Height (0-3) Normal (flat) 0 0-2 mm 1 2-5 mm 2 >5 mm 3 Range of Score 0-3, with 0 = best outcome, 3 = worst outcome Interpretation of Total Score: 0 = best outcome, 13 = worst outcome |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Healing | time to heal in days | Up To 90 Days After Treatment |
| Number of Participants With a Burn Wound Infection | Number of participants with a burn wound infection cellulitis |
Inclusion Criteria:
Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information. For subjects not able to provide informed consent (e.g., minors), a parent or legally authorized representative must provide consent. Assent must be provided as required by the Institutional Review Board (IRB).
Have one or more acute burns which:
Able to take in oral fluids.
Able to comply with the requirement for daily dressing changes, or have a caretaker who is able to comply.
Willing to make all required study visits.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dhaval Bhavsar, MD | University of Kansas Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | United States |
Not provided
| Label | URL |
|---|---|
| Initial study registration by study agent manufacturer before the study was modified and taken over by a new sponsor | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Collagenase Santyl | Applied topically (2 mm thickness once daily) Collagenase Santyl: A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP). |
| FG001 | Bacitracin | Applied topically (2 mm thickness) once daily Bacitracin: One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
This is descriptive statistics on the demographic information for each group, the bacitracin group and the santyl group.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Collagenase Santyl | Applied topically (2 mm thickness once daily) Collagenase Santyl: A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP). |
| BG001 | Bacitracin |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Subjects With at Least 95% Wound Healing | Outcome will be reported as number of subjects with at least 95% wound healing | Posted | Count of Participants | Participants | 21 Days After Treatment |
|
During course of the study, over 90 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Collagenase Santyl | Applied topically (2 mm thickness once daily) Collagenase Santyl: A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP). |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| rash | Skin and subcutaneous tissue disorders | Systematic Assessment | dermatitis |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Suzanne Mitchell, PhD, ARNP, FNP-BC, CWS | The University of Kansas Health System | 913-588-5000 | 6562 | smitchell3@kumc.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 7, 2018 | Nov 23, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D002056 | Burns |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| D001414 | Bacitracin |
| ID | Term |
|---|---|
| D010456 | Peptides, Cyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D010455 | Peptides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Bacitracin | Drug | One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams. |
|
|
| 90 Days After Treatment |
| Up to 90 Days After Treatment |
Applied topically (2 mm thickness) once daily Bacitracin: One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams. |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Fitzpatrick Skin Type | The Fitzpatrick skin classification is a measure of a person's skin pigment and propensity to form a hypertrophic scar. Lower Fitzpatrick Skin scores indicate a person's propensity to burn easily or scar easily. Type 1: Light, pale white, always burns, never tans. Type 2: Fair, white. Usually burns, sometimes tans. Type 3: Medium to olive. Sometimes burns, usually tans. Type 4: Olive. Rarely burns, always tans. Type 5: Brown, very rarely burns, always tans. Type 6: Dark brown to black, Never burns, always tans. | Count of Participants | Participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Number of Subjects With at Least 95% Wound Healing | Outcome will be reported as number of subjects with at least 95% wound epithelialization | number of participants healed after 14 days of treatment | Posted | Count of Participants | Participants | 14 days after treatment |
|
|
|
| Secondary | Vancouver Scar Scale | Scar appearance will be documented using the Vancouver Scar Scale. It assesses 4 variables: vascularity, height/thickness, pliability, and pigmentation. VSS is derived by adding the score for each variable. Details of VSS is below. The Vancouver Scar Scale Pigmentation (0-2) Normal 0 Hypopigmentation 1 Hyperpigmentation 2 Range of Score: 0-2 with 0 = best outcome, 2 = worst outcome Vascularity (0-3) Normal. 0 Pink 1 Red 2 Purple. 3 Range: 0-3 with 0 = best outcome, 3 = worst outcome Pliability (0-5) Normal 0 Supple 1 Yielding 2 Firm 3 Banding 4 Contracture 5 Range of Score: 0-5, with 0 = best outcome, 5 = worst outcome Height (0-3) Normal (flat) 0 0-2 mm 1 2-5 mm 2 >5 mm 3 Range of Score 0-3, with 0 = best outcome, 3 = worst outcome Interpretation of Total Score: 0 = best outcome, 13 = worst outcome | Posted | Count of Participants | Participants | 90 Days After Treatment |
|
|
|
| Other Pre-specified | Time to Healing | time to heal in days | Posted | Mean | Standard Deviation | days | Up To 90 Days After Treatment |
|
|
|
| Other Pre-specified | Number of Participants With a Burn Wound Infection | Number of participants with a burn wound infection cellulitis | Posted | Count of Participants | Participants | Up to 90 Days After Treatment |
|
|
|
| 0 |
| 8 |
| 0 |
| 8 |
| 1 |
| 8 |
| EG001 | Bacitracin | Applied topically (2 mm thickness) once daily Bacitracin: One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams. | 0 | 12 | 0 | 12 | 3 | 12 |
Not provided
Not provided
| D000602 |
| Amino Acids, Peptides, and Proteins |
| Score of 4 |
|
| Score of 8 |
|